Atrial fibrillation is a common comorbidity in pacemaker patients, associated with a three- to fivefold increased risk of stroke and a 1.5- to 1.9-fold increased mortality risk.
Atrial fibrillation
Pacemaker therapy
Epidemiological data from the Framingham heart study indicate that the cumulative incidence of atrial fibrillation (AF) over a 22 year follow up was 2.1% in men and 1.7% in women. The prevalence of AF increases with age, doubling with each successive decade, and 70% of people with AF are between 65–85 years old. AF is associated with a three- to fivefold increased risk of stroke, a threefold increased risk of congestive heart failure, and a significant 1.5- to 1.9-fold mortality risk even after adjusting for underlying cardiovascular conditions. Pacemaker follow up physicians often have to deal with AF as a co-morbidity. AF may also be associated with brady–tachy syndrome. A high incidence of AF will be present when we use pacemaker therapy after atrioventicular (AV) nodal ablation for medically refractory AF.
Building similarity graph...
Analyzing shared references across papers
Loading...
C.-P. Lau
Queen Mary Hospital
Heart
University of Hong Kong
Queen Mary Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
C.-P. Lau (Fri,) conducted a review in Atrial fibrillation. Pacemaker therapy was evaluated. Atrial fibrillation is a common comorbidity in pacemaker patients, associated with a three- to fivefold increased risk of stroke and a 1.5- to 1.9-fold increased mortality risk.
synapsesocial.com/papers/6a2226db9e220ae9ef4956bf — DOI: https://doi.org/10.1136/heart.89.1.106